Oral arsenic therapy for TP53-mutated blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).
- Your cancer must have a TP53 gene mutation (a change in a specific gene).
- If you have not had any prior treatment, you can join one group (Cohort A). If you have had one or more prior treatments that stopped working, you can join another group (Cohort B).
- You must be well enough to perform daily activities (ECOG score 0 to 2).
- You must agree to use effective contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding arsenic trioxide to the usual stem cell transplant procedure can lower the risk of leukemia coming back. It is for people with high-risk AML or MDS who have a specific TP53 gene change.
This trial tests a new drug (axatilimab) combined with two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation. The goal is to see if this combination helps control the cancer better than current treatments.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
This trial tests a combination of three drugs (hydroxychloroquine, decitabine, and venetoclax) for people with acute myeloid leukemia (AML) that is either hard to treat or very high-risk. The goal is to see if this combination can help control the leukemia and what side effects it may cause.
This trial tests if adding arsenic trioxide to standard chemotherapy can help children with cancers that have a certain p53 gene change. The goal is to see if the drug can reactivate the broken p53 protein to fight the tumor.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.